Literature DB >> 15929671

Disseminated medullary thyroid carcinoma despite early thyroid surgery in the multiple endocrine neoplasia-2A syndrome.

H M van Santen1, D C Aronson, A S P van Trotsenburg, F J W ten Kate, M D van de Wetering, W M Wiersinga, J J M de Vijlder, T Vulsma.   

Abstract

A 51/2-year-old boy, with a family history of multiple endocrine neoplasia (MEN)-2A syndrome, was evaluated for presence of MEN-2A and medullary thyroid carcinoma (MTC). DNA diagnostics confirmed MEN-2A. Basal (360 ng/L) and pentagastrin stimulated (430 ng/L) calcitonin (CT) levels were slightly elevated, plasma carcinoembryonic antigen (CEA) was normal. Within a year both tumor markers increased and total thyroidectomy was performed. Histologic examination did not show MTC. In the following years, both tumor markers increased progressively but despite the use of multiple imaging techniques no metastases were localized. After 6 years, biopsy of a palpable lymph node showed MTC. The boy was treated with total cervical, suprahyoidal, and mediastinal lymph node dissection, showing MTC in almost all nodes. Again, the tumor markers remained high. At this point in time, the disadvantages of further medical interventions were outweighed against the chance for cure and it was decided to shift the goal of treatment toward palliation rather than cure. At the last visit the boy was clinically well with persistent extremely high levels of plasma CEA and CT. In conclusion, when prophylactic thyroidectomy in the MEN-2A syndrome has failed, it may be best to withdraw from further interventions to prevent more damage.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15929671     DOI: 10.1089/thy.2005.15.485

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  1 in total

1.  An introduction to managing medullary thyroid cancer.

Authors:  Jan Willem de Groot; Thera P Links; Robert Mw Hofstra; John Tm Plukker
Journal:  Hered Cancer Clin Pract       Date:  2006-07-15       Impact factor: 2.857

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.